Summit Therapeutics (SMMT) closed at $14.63 on Oct 16, 2026, down 4.8% on the day. The stock is down 17.4% over the past month, up 8.4% over three months, down 16.4% year to date and down 35.4% over the past year. It trades 49.9% below its 52-week high of $29.23 and 21.2% above its 52-week low of $12.07. The close sits below its 50-day moving average ($15.68) and below its 200-day moving average ($16.30).
NextPick tracks SMMT in its Biotech basket alongside VRTX, MRNA, REGN, BIIB and ALNY. As of Oct 16, 2026, the basket's money-flow score is -8 (neutral), and the basket is down 3.4% over five sessions. Over the past month SMMT ranks 16th of 17 basket members by price change.
SMMT is scheduled to report earnings on Oct 19, 2026.
SMMT options were pricing 96% at-the-money implied volatility on Oct 12, 2026, an IV rank of 38 over the past year.
Summit Therapeutics is scheduled to report on Oct 19, 2026.
No — the Oct 16, 2026 close of $14.63 is 10.2% below the 200-day average of $16.30.
SMMT closed 49.9% below its 52-week high of $29.23.
NextPick groups SMMT with VRTX, MRNA, REGN, BIIB and ALNY in its Biotech basket.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
